New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) --  Biotech Acquisition Company (the "Company") (NASDAQ:BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on January 19, 2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the "Charter") and will redeem

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) (the "Company"), a publicly traded special purpose acquisition company, today announced that in connection with a proposed extension (the "Extension") of the time period the Company has to complete an initial business combination, as described in the Proxy Statement (as defined below), IREEM LLC, which has entered into an agreement to acquire the current sponsor's interest in the Company (as described in the Proxy Statement), will deposit into the Company's trust account (the "Trust Account") for each additional month the lesser of (i) an aggregate of $457,500 or (ii) $0.055 per share that remains outstanding an

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye Robbins, M.D., president and CEO, will participate in the "Drug Development in Pulmonary Medicine: Emerging Trends and a Review of the Unmet Need" panel discussion on Tuesday, August 9, 2022, 1:00 pm (ET), during the 2022 BTIG Biotechnology Conference, August 8 – 9, in New York City. Blade's lead investigational medicine is cudetaxestat, a non-competitive autotaxin inhibitor with direct anti-fibrotic activity and differentiating characteristics that is expected to enter a planned phase 2 clinical trial i

NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced that they have mutually agreed to terminate the previously announced Agreement and Plan of Merger (the "Merger Agreement"), effective immediately. As required by Cayman Islands law, BAC will convene the previously postponed extraordinary gene

Extraordinary General Meeting of BAC's shareholders postponed until a to-be-determined later dateNEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced the postponement of BAC's extraordinary general meeting of shareholders (the "Extraordinary Meeting") originally scheduled to be held on June 3, 2022. The Extraordinary Meeting has been postponed until a to-be determined later date. Once the new date of the Extra

Extraordinary General Meeting of BAC's shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern TimeNEW YORK and SOUTH SAN FRANCISCO, May 31, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San Francisco, Calif., today announced the postponement of BAC's extraordinary general meeting of shareholders (the "Extraordinary Meeting") originally scheduled to be held on June 1, 2022. The Extraordinary Meeting has been postponed until June 3, 2022, at 10:00 a.m. Eastern Time. As previously a

NEW YORK, May 24, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a submission to the United States Securities and Exchange Commission ("SEC") of a prospectus supplement containing information supplements and updates to the information contained in the proxy statement/prospectus dated May 9, 2022, included in Amendment No. 4 to the registration statement on Form S-4 (File No. 333-263577), relating to its previously announced proposed business combination with Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company based in South San

Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model Non-competitive autotaxin inhibition by cudetaxestat maintained potency in the presence of elevated substrate concentrations found in fibrotic tissues Company on track to start phase 2 clinical trial of cudetaxestat in patients with idiopathic pulmonary fibrosis (IPF) in second quarter of 2022 Blade Therapeutics, Inc., a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced new data from preclinical studies that highlight the differentiating characteristics of cudetaxestat, an inve

No significant drug-drug interaction (DDI) seen with cudetaxestat in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF) Cudetaxestat was well tolerated and showed no reports of treatment-related serious adverse events when co-administered with either pirfenidone or nintedanib in healthy volunteers In vivo pharmacokinetics study showed no significant effect of cudetaxestat on pirfenidone or nintedanib exposures when co-administered with either medication Company on track to start phase 2 clinical trial of cudetaxestat dosed either as monotherapy or co-administered with pirfenidone or nintedanib in patients with IPF in seco

Extraordinary General Meeting of BAC's shareholders is scheduled for June 1, 2022, at 10:00 a.m., Eastern TimePost-closing company will be renamed "Blade Biotherapeutics, Inc." upon Business Combination closing, with common stock and warrants expected to trade on the Nasdaq Global Market under ticker symbols "BBTX" and "BBTXW"Post-closing company has secured up to $75 million in financing under a committed equity facility with an affiliate of Cantor FitzgeraldNEW YORK and SOUTH SAN FRANCISCO, Calif., May 9, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ:BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeut

Blade Therapeutics, Inc. ("Blade"), a biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development. In this role, Dr. Elmankabadi will oversee strategy and execution of Blade's clinical development programs. "Dr. Elmankabadi has an extensive track record driving drug development from proof-of-concept through launch across multiple therapeutic areas," said Wendye Robbins, M.D., president and CEO of Blade. "I am thrilled to welcome Dr. Elmankabadi to the Blade team as we seek to advance our clinical-stage pipeline t

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

SC 13G - Biotech Acquisition Co (0001825413) (Subject)

SC 13G/A - Biotech Acquisition Co (0001825413) (Subject)

15-12G - Biotech Acquisition Co (0001825413) (Filer)

25-NSE - Biotech Acquisition Co (0001825413) (Subject)

8-K - Biotech Acquisition Co (0001825413) (Filer)

8-K - Biotech Acquisition Co (0001825413) (Filer)

8-K - Biotech Acquisition Co (0001825413) (Filer)

DEF 14A - Biotech Acquisition Co (0001825413) (Filer)

8-K - Biotech Acquisition Co (0001825413) (Filer)

PRE 14A - Biotech Acquisition Co (0001825413) (Filer)

NT 10-Q - Biotech Acquisition Co (0001825413) (Filer)

8-K - Biotech Acquisition Co (0001825413) (Filer)